Bio Japan, established in 1986, is a premier industry gathering that spans biopharmaceuticals, regenerative medicine, and digital healthcare. This year’s event expects participation from 1,139 companies and more than 18,000 attendees, reaffirming its role as a key platform for global biotech collaboration.
Samsung Biologics is leveraging its presence to expand its client base, targeting not only the top 20 global pharmaceutical companies but also those ranked in the top 40. The company’s booth will highlight its advanced manufacturing capabilities, including a total production capacity of 784,000 liters across its facilities, with its fifth plant alone providing 180,000 liters. A key focus will be its antibody-drug conjugate (ADC) production capabilities, bolstered by a dedicated ADC facility that began operations in March 2025. The company will also showcase its integrated contract development organization (CDO) platform, emphasizing its comprehensive CDMO services tailored to diverse biopharmaceutical needs.
On the opening day, James Choi, Vice President of Business Development, and Kevin Sharp, Vice President of Sales and Operations, will deliver a presentation titled “Strategic Outsourcing for Supply Chain Resilience and Integrated Development and Manufacturing Services for Diverse Biopharmaceutical Modalities.” The session will underscore Samsung Biologics’ commitment to addressing supply chain challenges and supporting innovative drug development.
Samsung Biologics’ focus on Japan aligns with the country’s significant role in the global biopharmaceutical market, where efficient and reliable CDMO services are increasingly in demand. The company’s continued investment in state-of-the-art facilities and strategic partnerships positions it as a key player in the global biotech supply chain.
Kim Kuk Ju, HEALTH IN NEWS TEAM
press@hinews.co.kr
